The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
ALHEMO (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
ALHEMO
Date registered
Evaluation commenced
Decision date
Approval time
188 (255 working days)
Active ingredients
concizumab
Registration type
EOI
Indication
Alhemo is indicated where prophylaxis is required to prevent or reduce the frequency of bleeding in patients at least 12 years of age who have:
- haemophilia B (congenital factor IX [FIX] deficiency)
- haemophilia A (congenital factor VIII [FVIII] deficiency)